← back to search

Michael F. Dixon

Fera Science (United Kingdom) · US
Area of research
Surgery · Pathology and Forensic Medicine
Research interest
Research interests include Helicobacter pylori-related gastroenterology studies, Genetic factors in colorectal cancer, Gastric Cancer Management and Outcomes, and Eosinophilic Esophagitis.
h-index
74
citations
23,992
works
276
NIH funding
—
primary concept
Medicine
email
m.dixon@nhsalliance.org

Recent publications

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
Annals of Oncology 2022cited by 247position: middledoi
Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation
Journal for ImmunoTherapy of Cancer 2020cited by 200position: middledoi

Grants

Collaborative Research: ELEMENTS: The LROSE Science Gateway LIDAR/RADAR Analysis In The Cloud
NSF2103785$295,9652021–2025PIRePORTER

Frequent collaborators

Michael J. Overman · The University of Texas MD Anderson Cancer Center1 papers (2022–2022)Ray McDermott · University College Dublin1 papers (2022–2022)Scott Kopetz · The University of Texas MD Anderson Cancer Center1 papers (2022–2022)Ming Lei · China Astronaut Research and Training Center1 papers (2022–2022)Ka Yeung Mark Wong · Azienda Unita' Sanitaria Locale Di Modena1 papers (2022–2022)Arteid Memaj · Bristol-Myers Squibb (United States)1 papers (2022–2022)Sara Lonardi · Istituto Oncologico Veneto1 papers (2022–2022)Alain Hendlisz · Institut Jules Bordet1 papers (2022–2022)Andrew Hill · Manukau Institute of Technology1 papers (2022–2022)Fabio Gelsomino · Azienda Unita' Sanitaria Locale Di Modena1 papers (2022–2022)Michael B. Sawyer · The University of Adelaide1 papers (2022–2022)Thierry André · Inserm1 papers (2022–2022)Bart Neyns · Belgian Society of Medical Oncology1 papers (2022–2022)Eric Van Cutsem · KU Leuven1 papers (2022–2022)Massimo Aglietta · University of Turin1 papers (2022–2022)Michael A. Morse · Zhejiang University1 papers (2022–2022)H-J Lenz · University of Southern California1 papers (2022–2022)Sandzhar Abdullaev · Bristol-Myers Squibb (Germany)1 papers (2022–2022)